Probiodrug

  • Accelerated bookbuild offering amounting to €14.9m.
  • Proceeds will be used to finance clinical development of their lead product and to support exploration and development of additional business opportunities.
  • Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner in the transaction.